Silver Book

Silver Book Fact

Through advances in risk-factor assessment, detection, and preventive strategies, the average age of acute myocardial infarction and heart failure patients has shifted around 10 to 15 years forward. One-year acute myocardial infarction mortality (after making it to the hospital alive) has decreased from 40% to 4-8%, in the last 20 years. One-year mortality for heart failure patients was reduced from 50% to 25% over that same time period.

Weisfeldt M, Zeiman S. Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease. Health Aff. 2007; 26(1): 25-37. http://content.healthaffairs.org/cgi/content/full/26/1/25

Reference

Title
Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease
Publication
Health Aff
Publication Date
2007
Authors
Weisfeldt M, Zeiman S
Volume & Issue
Volume 26, Issue 1
Pages
25-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • If all untreated patients with Stage I or II hypertension had been treated and achieved normal blood pressures, there would have been 420,000 fewer hospital discharges in 2002 than actually…  
  • According to the Pharmaceutical Research and Manufacturers of America, 146 new medicines are being developed for heart disease and stroke. They include 17 for stroke, 16 for congestive heart failure,…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…